Business Overview: Fortrea Holdings Inc. (NASDAQ: FTRE)

---

Executive Summary

Fortrea Holdings Inc. is a global contract research organization (CRO) that manages clinical trials and provides consulting services for pharmaceutical, biotechnology, and medical device companies. Fortrea was spun off from Labcorp on June 29, 2023, inheriting more than 30 years of clinical-trial operating history, and is headquartered in Durham, North Carolina.

The company runs trials in roughly 100 countries through about 62 operating facilities, with its Clinical Development service line — spanning Phase I-IV trials, regulatory, biostatistics, and pharmacovigilance work — generating the large majority of revenue. In 2025 Fortrea reported $2.72 billion in revenue, positioning it as one of the handful of truly global, full-service CROs able to run large, multi-country trials for both large pharma and smaller biotech sponsors.

---

1. Core Business Model & How They Work

Fortrea is paid by biopharma and medical-device sponsors to design, staff, and run the clinical trials required to win regulatory approval for new drugs and devices. Revenue is earned under multi-year, milestone- and pass-through-cost-based contracts tied to patient enrollment and trial progress.

[ Sponsor has drug/device candidate ] ➡️ [ Fortrea designs & staffs trial (sites, patients, data) ] ➡️ [ Trial execution (Phase I-IV) ] ➡️ [ Data management, biostatistics, regulatory submission support ] ➡️ [ Milestone & pass-through billing over multi-year contract ]

Key Operational Drivers

1. Delivery model flexibility: Fortrea offers Full Service (Fortrea runs the entire project), Functional Service Provider (FSP) (targeted staffing augmentation embedded in a sponsor's own trial organization), and a Hybrid blend — letting it compete for both full outsourcing and staffing-style engagements.
2. Backlog-funded revenue: Trials run for years, so revenue is substantially pre-sold via a multi-year backlog that converts to revenue as enrollment and trial milestones are hit.
3. Scale and therapeutic depth: Over 30 years of experience across 20+ therapeutic areas; from January 2020 through December 2024 the company ran more than 5,930 clinical-development trial projects covering roughly 1,000,000 subjects. Oncology alone made up about 40% of full-service therapeutic-based revenue in 2025.
4. Technology partnerships: Fortrea works with third-party platforms including Advarra, Cognizant, Medidata, and Veeva rather than building all trial technology in-house, and is investing in AI and data tools to improve trial efficiency.

---

2. Business Segments

Fortrea reports a single segment, Clinical Services, following the 2024 divestiture of its former Enabling Services segment (Fortrea Patient Access and Endpoint Clinical, sold to an affiliate of Arsenal Capital Partners and now reported as discontinued operations). Per the company's own disclosure and this guide's standard, no segment breakdown is presented here since the ongoing business is genuinely single-segment.

Service Lines Within Clinical Services

• Clinical Pharmacology — First-in-human and exploratory studies run through four dedicated clinical research units (Leeds, Dallas, Daytona, Madison), each with 88-100 beds.
• Clinical Development — The largest revenue contributor for five consecutive years: Phase I-IV trial management, real-world evidence, site/patient recruitment, data management, biostatistics, pharmacovigilance, and medical writing, plus a dedicated device/diagnostics unit that ran 500+ studies from 2020-2024.
• Consulting Services — Product development and regulatory strategy, market access, and health economics and outcomes research (HEOR).

---

3. Product Portfolio (Key Service Offerings)

---

4. Competitive Landscape

The CRO industry is highly fragmented: hundreds of small, limited-scope providers compete alongside a small number of large, global full-service CROs.

GLOBAL CRO POSITIONING
┌────────────────────────────────────────────────────────────────┐
│ High   [IQVIA]                                                 │
│  ▲     (Largest, data+tech scale)    [ICON plc]                │
│  G                                   (Large, M&A-driven scale)  │
│  L           [Fortrea]  [Parexel]                               │
│  O           (Global, pharma-heavy)  [PPD/Thermo Fisher]        │
│  B                                                               │
│  A                      [Medpace]    [Smaller regional/niche    │
│  L                      (Mid-size,    CROs, site networks,      │
│                          biotech-focused) in-house sponsor R&D] │
│ Low                                                              │
│  └──────────────────────────────────────────────────────────►  │
│  Low         SPONSOR CONCENTRATION / THERAPEUTIC BREADTH   High │
└────────────────────────────────────────────────────────────────┘

• Large full-service CROs — IQVIA, ICON plc, Parexel, and Thermo Fisher's PPD unit are Fortrea's closest scale peers; all compete for the same large, multi-country Phase II-IV trials from big pharma sponsors.
• Mid-size/biotech-focused CROs — Medpace and others compete more narrowly, often winning smaller biotech sponsors on speed and relationship depth.
• In-house sponsor R&D and site networks — Some sponsors run trials internally rather than outsourcing; separately, some competitors have acquired clinical site networks outright, which can give them priority access to patient-recruitment sites that Fortrea must otherwise access through partnerships.
• Universities, teaching hospitals, and site management organizations — Compete narrowly for specific trial site or specialty work rather than as full-service alternatives.

Fortrea positions itself as more flexible and customer-focused than the largest competitors, while still offering the global scale (100 countries, 62 facilities) that smaller regional CROs lack.

---

5. Strategic Strengths & Risks

Strengths (Moat Sources)

• Scale and global regulatory footprint — Operating in ~100 countries with deep, accumulated relationships with regulators and investigator sites is difficult and slow for a new entrant to replicate.
• Customer embedding and switching costs — Sponsors typically use three or more Fortrea services simultaneously, and mid-trial CRO changes are operationally disruptive and risky for drug approval timelines, discouraging switching once a trial is underway.
• Therapeutic depth in oncology — ~40% of full-service therapeutic revenue comes from oncology, an area requiring specialized trial design expertise that is hard to build from scratch.

Risks

• Customer concentration — One customer alone represented about 18.1% of 2025 revenue, and the top 20 customers represented roughly 69% of 2025 revenue (up from 61% in 2023), meaning the loss of a small number of large pharma relationships would be disproportionately damaging.
• Post-spinoff standalone cost structure — As a company separated from Labcorp in 2023, Fortrea has had to build out standalone systems and has booked a large non-cash goodwill impairment of $797.9 million in 2025, contributing to a full-year net loss of $(986.2) million.
• Site-network consolidation by competitors — Competitors acquiring proprietary site networks could squeeze Fortrea's access to patient-recruitment capacity over time.
• Biopharma R&D funding cyclicality — CRO demand is tied to sponsor R&D budgets and biotech funding conditions, which can slow new contract awards in a tighter funding environment.

---

6. Financial Overview

---

7. Summary Conclusion

Fortrea is a scaled, global, single-segment CRO whose moat rests on the operational difficulty of replicating a multi-country trial-delivery network and the switching costs sponsors face once a trial is underway — not on patent-like legal protection. Its 2025 results show the business is still digesting its 2023 spinoff from Labcorp (standalone cost build-out, a large goodwill impairment) while revenue has plateaued and customer concentration has risen. The central forward question is whether Fortrea can stabilize bookings and improve margins as a standalone company while fending off both larger-scale peers (IQVIA, ICON, PPD) and smaller, more specialized CROs, without the benefit of a parent company's balance sheet.